Viridian Therapeutics Inc VRDN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
-
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
-
Viridian Therapeutics Says FDA Approves Lumvoa to Treat Thyroid Eye Disease
-
Viridian Shares Fall After Competing Amgen Eye Drug Performs Well
-
Viridian Therapeutics in Royalty Financing Deal With DRI Healthcare for Up to $300 Million
Trading Information
- Previous Close Price
- $18.99
- Day Range
- $18.92–19.55
- 52-Week Range
- $13.18–34.29
- Bid/Ask
- $18.77 / $19.43
- Shares Outstanding
- 113.29M
- Market Cap
- $2.20B
- Volume/Avg
- 2M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 25.79
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 252
Valuation
|
Metric
|
VRDN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.81 |
Price/Sales | 25.79 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VRDN
|
|---|---|
Quick Ratio | 16.56 |
Current Ratio | 16.95 |
Interest Coverage | −25.69 |
Quick Ratio
VRDN
Profitability
|
Metric
|
VRDN
|
|---|---|
Return on Assets (Normalized) | −42.25% |
Return on Equity (Normalized) | −72.52% |
Return on Invested Capital (Normalized) | −50.70% |
Return on Assets
VRDN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|V@>gYq | LOCK|jnqq^ | $128B | |||
| Moderna Inc
MRNA
| LOCK|Kt$c!w | LOCK|w%T | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@%LCS< | LOCK|G<Bnx | $76B | |||
| argenx SE ADR
ARGX
| LOCK|qW<x<Vh | LOCK|&$ | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|vhwt>R% | LOCK|Z# | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&&gmL@ | LOCK|#md^ | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|H!wy!SW | LOCK|%Dfv | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|V#FL%x> | LOCK|@W | $24B | |||
| Incyte Corp
INCY
| LOCK|y&C<s$# | LOCK|Nl | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<&G>p@ | LOCK|H! | $15B |
United States